The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cannabis Global's Revenue for the
three
months ended in May. 2022 was $0.79 Mil. Cannabis Global's average Accounts Receivable for the
three
months ended in May. 2022 was $0.43 Mil.
Hence, Cannabis Global's Receivables Turnover for the
three
months ended in May. 2022 was 1.85.
Cannabis Global (OTCPK:CBGL) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Cannabis Global Receivables Turnover Related Terms
Cannabis Global Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Cannabis Global's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CBGL vs MILC, BBBT, GCAN: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Global's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannabis Global Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannabis Global's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Cannabis Global's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannabis Global (CBGL) has a Receivables Turnover of 1.85 as of May. 2022. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cannabis Global and its competitors.
Is Cannabis Global's Receivables Turnover too high?
Cannabis Global's current Receivables Turnover is 1.85. The Drug Manufacturers industry median Receivables Turnover is 5.07. Cannabis Global's value of 1.85 is 63.5% below this industry median.
How does Cannabis Global's Receivables Turnover compare to MILC and BBBT?
Cannabis Global's Receivables Turnover of 1.85 can be compared against companies in the Drug Manufacturers industry. The industry median Receivables Turnover is 5.07. Cannabis Global's value of 1.85 is 63.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannabis Global's current Receivables Turnover of 1.85 is 63.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cannabis Global and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannabis Global's current Receivables Turnover is 1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabis Global stock overvalued right now?
Cannabis Global (CBGL) has a current Receivables Turnover of 1.85. The current Receivables Turnover is 1.85 and 63.5% below the Drug Manufacturers industry median of 5.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Cannabis Global (CBGL), the current Receivables Turnover is 1.85 as of May. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cannabis Global Inc manufactures and distributes various cannabis products via its majority ownership of Natural Plant Extract, Inc is developing the Ethos Comply Bag, and generally conducts research and development in the areas of hemp, cannabis and consumer food goods. The company also have an active research and development program focused on creating and commercializing engineered technologies that deliver hemp extracts and cannabinoids to the human body. Its product includes cannabis flower packaged in various weights, cannabis Pre-rolls, cannabis edible products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBGL has been successfully added to your 